Squarepoint Ops LLC Vertex Pharmaceuticals Inc Transaction History

Squarepoint Ops LLC

$99.2 Billion
Q4 2024

A detailed history of Squarepoint Ops LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Squarepoint Ops LLC holds 9,092 shares of VRTX stock, worth $4.17 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

9,092

Previous 7,930 14.65%

Holding current value

$4.17 Million

Previous $3.69 Million 0.73%

% of portfolio

0.0%

Previous 0.01%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$396.64 - $516.74 $460,895 - $600,451	1,162 Added 14.65%	9,092 $3.66 Million
Q3 2024 Nov 14, 2024	SELL	$460.0 - $505.78 $7.9 Million - $8.69 Million	-17,173 Reduced 68.41%	7,930 $3.69 Million
Q2 2024 Aug 14, 2024	SELL	$392.81 - $485.53 $12 Million - $14.8 Million	-30,464 Reduced 54.82%	25,103 $11.8 Million
Q1 2024 May 15, 2024	BUY	$407.69 - $446.08 $13.9 Million - $15.2 Million	34,157 Added 159.54%	55,567 $23.2 Million
Q4 2023 Feb 14, 2024	BUY	$343.0 - $410.68 $3.96 Million - $4.74 Million	11,540 Added 116.92%	21,410 $8.71 Million
Q2 2023 Aug 14, 2023	SELL	$314.42 - $351.91 $941,373 - $1.05 Million	-2,994 Reduced 23.27%	9,870 $3.47 Million
Q1 2023 May 15, 2023	SELL	$283.23 - $323.1 $8.68 Million - $9.9 Million	-30,633 Reduced 70.43%	12,864 $4.05 Million
Q4 2022 Feb 14, 2023	BUY	$285.76 - $321.48 $12.4 Million - $14 Million	43,497 New	43,497 $12.6 Million
Q1 2022 May 16, 2022	SELL	$221.42 - $260.97 $11 Million - $12.9 Million	-49,545 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $18.4 Million - $23.3 Million	-104,211 Reduced 67.78%	49,545 $10.9 Million
Q3 2021 Nov 15, 2021	BUY	$181.39 - $202.99 $11.9 Million - $13.4 Million	65,841 Added 74.89%	153,756 $27.9 Million
Q2 2021 Aug 16, 2021	SELL	$187.49 - $221.1 $8.69 Million - $10.2 Million	-46,326 Reduced 34.51%	87,915 $17.7 Million
Q1 2021 May 17, 2021	BUY	$207.02 - $241.31 $26.4 Million - $30.7 Million	127,401 Added 1862.59%	134,241 $28.8 Million
Q4 2020 Feb 16, 2021	SELL	$207.01 - $276.09 $12.1 Million - $16.1 Million	-58,448 Reduced 89.52%	6,840 $1.62 Million
Q3 2020 Nov 16, 2020	BUY	$255.65 - $303.1 $8.81 Million - $10.4 Million	34,443 Added 111.66%	65,288 $17.8 Million
Q2 2020 Aug 14, 2020	BUY	$225.48 - $295.8 $3.89 Million - $5.1 Million	17,245 Added 126.8%	30,845 $8.96 Million
Q1 2020 May 15, 2020	SELL	$199.77 - $247.81 $16.2 Million - $20.1 Million	-80,957 Reduced 85.62%	13,600 $3.24 Million
Q4 2019 Feb 14, 2020	BUY	$166.71 - $223.91 $6.39 Million - $8.58 Million	38,332 Added 68.18%	94,557 $20.7 Million
Q3 2019 Nov 14, 2019	SELL	$166.23 - $187.09 $1.04 Million - $1.17 Million	-6,264 Reduced 10.02%	56,225 $9.53 Million
Q2 2019 Aug 14, 2019	SELL	$164.61 - $190.37 $20.8 Million - $24 Million	-126,119 Reduced 66.87%	62,489 $11.5 Million
Q1 2019 May 15, 2019	BUY	$163.73 - $194.7 $10.1 Million - $12 Million	61,694 Added 48.61%	188,608 $34.7 Million
Q4 2018 Feb 14, 2019	BUY	$151.91 - $192.21 $8.43 Million - $10.7 Million	55,522 Added 77.77%	126,914 $21 Million
Q3 2018 Nov 14, 2018	BUY	$167.73 - $192.74 $8.54 Million - $9.81 Million	50,892 Added 248.25%	71,392 $13.8 Million
Q2 2018 Aug 14, 2018	SELL	$145.72 - $169.96 $13.5 Million - $15.8 Million	-92,729 Reduced 81.9%	20,500 $3.48 Million
Q1 2018 May 15, 2018	BUY	$151.6 - $177.13 $17.2 Million - $20.1 Million	113,229 New	113,229 $18.5 Million
Q4 2017 Feb 14, 2018	SELL	$137.28 - $155.55 $11.9 Million - $13.5 Million	-86,597 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$148.13 - $162.24 $12.8 Million - $14 Million	86,597	86,597 $13.2 Million

Others Institutions Holding VRTX

# of Institutions

1,751

Shares Held

227M

Call Options Held

1.64M

Put Options Held

1.47M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $118B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.

Account

Squarepoint Ops LLC Vertex Pharmaceuticals Inc Transaction History